HIMS Quote, Financials, Valuation and Earnings

Grove Collaborative Holdings has a net margin of 5.41% compared to Hims & Hers Health's net margin of -25.53%. Hims & Hers Health's return on equity of 32.03% beat Grove Collaborative Holdings's return on equity of -154.22%.

Hims & Hers Health has a consensus price target of $44.82, signalling upside risk potential of 67.79%. On the other hand Grove Collaborative Holdings has an analysts' consensus of $2.50 which suggests that it could grow by 133.65%. Given that Grove Collaborative Holdings has higher upside potential than Hims & Hers Health, analysts believe Grove Collaborative Holdings is more attractive than Hims & Hers Health.

Hims & Hers Health has a beta of 1.654, which suggesting that the stock is 65.449% more volatile than S&P 500. In comparison Grove Collaborative Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hims & Hers Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Grove Collaborative Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health pays -- of its earnings as a dividend. Grove Collaborative Holdings pays out -- of its earnings as a dividend.

Hims & Hers Health quarterly revenues are $481.1M, which are larger than Grove Collaborative Holdings quarterly revenues of $49.5M. Hims & Hers Health's net income of $26M is higher than Grove Collaborative Holdings's net income of -$12.6M. Notably, Hims & Hers Health's price-to-earnings ratio is 49.46x while Grove Collaborative Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health is 4.28x versus 0.19x for Grove Collaborative Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Kenvue has a net margin of 5.41% compared to Hims & Hers Health's net margin of 8%. Hims & Hers Health's return on equity of 32.03% beat Kenvue's return on equity of 9.84%.

Hims & Hers Health has a consensus price target of $44.82, signalling upside risk potential of 67.79%. On the other hand Kenvue has an analysts' consensus of $24.21 which suggests that it could grow by 5.53%. Given that Hims & Hers Health has higher upside potential than Kenvue, analysts believe Hims & Hers Health is more attractive than Kenvue.

Hims & Hers Health has a beta of 1.654, which suggesting that the stock is 65.449% more volatile than S&P 500. In comparison Kenvue has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hims & Hers Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kenvue offers a yield of 3.55% to investors and pays a quarterly dividend of $0.21 per share. Hims & Hers Health pays -- of its earnings as a dividend. Kenvue pays out 150.68% of its earnings as a dividend.

Hims & Hers Health quarterly revenues are $481.1M, which are smaller than Kenvue quarterly revenues of $3.7B. Hims & Hers Health's net income of $26M is lower than Kenvue's net income of $293M. Notably, Hims & Hers Health's price-to-earnings ratio is 49.46x while Kenvue's PE ratio is 43.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health is 4.28x versus 2.85x for Kenvue. Usually stocks with elevated PS ratios are considered overvalued.

The Beauty Health has a net margin of 5.41% compared to Hims & Hers Health's net margin of -12.37%. Hims & Hers Health's return on equity of 32.03% beat The Beauty Health's return on equity of -47.95%.

Hims & Hers Health has a consensus price target of $44.82, signalling upside risk potential of 67.79%. On the other hand The Beauty Health has an analysts' consensus of $1.58 which suggests that it could grow by 66.49%. Given that Hims & Hers Health has higher upside potential than The Beauty Health, analysts believe Hims & Hers Health is more attractive than The Beauty Health.

Hims & Hers Health has a beta of 1.654, which suggesting that the stock is 65.449% more volatile than S&P 500. In comparison The Beauty Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hims & Hers Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Beauty Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health pays -- of its earnings as a dividend. The Beauty Health pays out -- of its earnings as a dividend.

Hims & Hers Health quarterly revenues are $481.1M, which are larger than The Beauty Health quarterly revenues of $83.5M. Hims & Hers Health's net income of $26M is higher than The Beauty Health's net income of -$10.3M. Notably, Hims & Hers Health's price-to-earnings ratio is 49.46x while The Beauty Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health is 4.28x versus 0.39x for The Beauty Health. Usually stocks with elevated PS ratios are considered overvalued.